Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Cadribine | Mavenclad | 4.5. Interactions with other medicinal products | Interactions with immunosuppressive medicinal product | Feb,2023 |
| Clarithromycin | Klacid XL | 4.4 Special Warnings and Special Precautions for Use | Risk of Cardiovascular Events | May,2024 |
| Nifedipine | Adalat | 4.5. Interactions with other medicinal products | Interaction with Verapamil, Doxazosin, Cisapride, Metformin, St. John’s Wort , Acarbose, diuretics, PDE5 inhibitors, and alpha-methyldopa | Feb,2023 |
| Rotavirus Vaccine | Rotarix | 4.5. Interactions with other medicinal products | Interactions with Immunosuppressive therapies | Feb,2023 |
| Phenytoin | Accofil | 4.4 Special Warnings and Special Precautions for Use | Pulmonary adverse effects, Glomerulonephritis, Capillary leak syndrome, Splenomegaly and splenic rupture | May,2024 |
| Ondansetron | Dansetron | 4.5. Interactions with other medicinal products | Carmustine do not affect the pharmacokinetics of ondansetron | Feb,2023 |